Login to Your Account



Panel Votes in Favor of GSK Drug

ODAC Flattens Taltorvic, Cites Risk/Benefit Profile in Sarcoma

By Catherine Shaffer
Staff Writer

Wednesday, March 21, 2012

The FDA's oncologic drugs advisory committee (ODAC) voted 13 to 1 against the approval of Taltorvic (ridaforolimus) by Ariad Pharmaceuticals Inc., partnered with Merck & Co. Inc., for soft-tissue and bone sarcoma.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription